Duke, AIS Announce Collaboration To Build Cell Processing Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

DURHAM, NC--Duke University Medical Center and ExVivo Therapies have announced a collaboration to construct and operate a cell processing center, the first on the East Coast. ExVivo is a joint venture between Applied Immune Sciences (AIS) and Rhône-Poulenc Rorer.

DURHAM, NC--Duke University Medical Center and ExVivo Therapieshave announced a collaboration to construct and operate a cellprocessing center, the first on the East Coast. ExVivo is a jointventure between Applied Immune Sciences (AIS) and Rhône-PoulencRorer.

The Durham center, due for completion in late 1995, will processcells to be used in clinical trials of cell and gene therapiesfor certain forms of cancer, AIDS, and other diseases.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content